Showing results (1601-1610 of 1,671) with videos related to

Sort By:
Pageof 168
Diabetes Care|October 16, 2014
Roux-en-Y gastric bypass surgery, but not calorie restriction, reduces plasma branched-chain amino acids in obese women independent of weight loss or the presence of type 2 diabetesMirjam A Lips, Jan B Van Klinken, Vanessa van Harmelen, et al.
Breast Cancer Research and Treatment|January 6, 2015
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)S de Groot, L G M Janssen, A Charehbili, et al.
Biomaterials|March 4, 2017
In situ heart valve tissue engineering using a bioresorbable elastomeric implant - From material design to 12 months follow-up in sheepJolanda Kluin, Hanna Talacua, Anthal I P M Smits, et al.
Annals of Hematology|April 11, 2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study groupNoortje Thielen, Bronno van der Holt, Gregor E G Verhoef, et al.
Nature|June 5, 2014
Genome sequencing identifies major causes of severe intellectual disabilityChristian Gilissen, Jayne Y Hehir-Kwa, Djie Tjwan Thung, et al.
Journal of Medical Genetics|July 5, 2018
Genetic obesity: next-generation sequencing results of 1230 patients with obesityLotte Kleinendorst, Maarten P G Massink, Mellody I Cooiman, et al.
Cell Reports|December 13, 2018
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal HematopoiesisHan J M P Verhagen, Noortje van Gils, Tania Martiañez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Developmental Biology|December 24, 2013
Reduced Euchromatin histone methyltransferase 1 causes developmental delay, hypotonia, and cranial abnormalities associated with increased bone gene expression in Kleefstra syndrome miceMonique C M Balemans, Muhammad Ansar, Astrid R Oudakker, et al.
Pageof 168